Frontiers in oncology · 2025
Acute obinutuzumab-induced thrombocytopenia in follicular lymphoma: case report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Jieyi, Chen Miaomiao, Zhang Yi, Xu Ce, Li Rong
Аннотация
INTRODUCTION: Obinutuzumab, a type II anti-CD20 monoclonal antibody used in the treatment of follicular lymphoma, is associated with a higher incidence of adverse events, including thrombocytopenia, compared to rituximab. We report a case of severe, acute thrombocytopenia induced by obinutuzumab and explore its potential mechanism.
CASE PRESENTATION: A 47-year-old woman with follicular lymphoma developed recurrent, severe (grade III-IV) thrombocytopenia within 24 h following obinutuzumab administration, starting from her second treatment cycle. Subsequent bone marrow aspiration revealed significant megakaryocyte hyperplasia but with impaired platelet production. Key laboratory findings included elevated levels of pro-inflammatory cytokines TNF-α and IL-6, decreased complement levels, and reduced IgM, while the platelet antibodies tested were negative. The patient's thrombocytopenia was managed and improved with treatments including recombinant human thrombopoietin (rhTPO) and platelet transfusions.
CONCLUSION: Obinutuzumab can rarely cause acute, severe thrombocytopenia, possibly through a combination of immune-mediated platelet destruction and impaired megakaryocyte maturation.
CASE PRESENTATION: A 47-year-old woman with follicular lymphoma developed recurrent, severe (grade III-IV) thrombocytopenia within 24 h following obinutuzumab administration, starting from her second treatment cycle. Subsequent bone marrow aspiration revealed significant megakaryocyte hyperplasia but with impaired platelet production. Key laboratory findings included elevated levels of pro-inflammatory cytokines TNF-α and IL-6, decreased complement levels, and reduced IgM, while the platelet antibodies tested were negative. The patient's thrombocytopenia was managed and improved with treatments including recombinant human thrombopoietin (rhTPO) and platelet transfusions.
CONCLUSION: Obinutuzumab can rarely cause acute, severe thrombocytopenia, possibly through a combination of immune-mediated platelet destruction and impaired megakaryocyte maturation.